FDA Brief

Warning letters Drugs

FDA warning letter to

Lauren R. Klein, MD, M.S.

High riskIssued May 6, 2021Posted Oct 19, 2021Center for Drug Evaluation and Research | CDER

FDA cited Dr. Lauren R. Klein for running two emergency department drug studies without required investigational new drug applications.

What happened

FDA inspected Dr. Klein’s clinical site from April 9 to April 23, 2019, as part of its Bioresearch Monitoring Program. FDA found that she acted as sponsor-investigator for Protocol HSR 17-4345 (olanzapine, haloperidol, ziprasidone, midazolam) and Protocol HSR 18-4521 (olanzapine, midazolam) without submitting or having an IND in effect. FDA also found the studies did not meet the IND exemption because they did not exclude subjects with liver or kidney dysfunction or subjects taking interacting drugs.

What FDA found

  1. Ran Protocol HSR 17-4345, giving olanzapine, haloperidol, ziprasidone, or midazolam to emergency department patients, without an IND in effect.

    21 CFR 312.20 and 312.40(a)
  2. Ran Protocol HSR 18-4521, giving olanzapine or midazolam to emergency department patients, without an IND in effect.

    21 CFR 312.20 and 312.40(a)
  3. Did not qualify for the IND exemption because the protocols did not exclude subjects with liver or kidney dysfunction or subjects taking drugs that interact with the study drugs, which increased risks.

    21 CFR 312.2(b)(1)(iii)

What FDA wants

Within 15 business days of receiving the letter, notify FDA in writing of actions taken to prevent similar violations and address the deficiencies.

Who should pay attention

  • sponsor-investigators running drug studies at hospitals
  • IRBs reviewing emergency department research
  • clinical research sites using marketed drugs in protocols

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  2. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  3. Ehsan Sadri, M.D.

    FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.

    High risk
  4. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk